Egalet Corporation has announced that the FDA has approved Arymo ER (morphine sulfate) extended-release (ER) tablets C-II for the management...
Endo International plc continues to believe in the safety, efficacy, and favorable benefit-risk profile of Opana ER (oxymorphone hydrochloride extended...
Egalet Corporation announced that the FDA has accepted the new drug application (NDA) for Arymo ER (morphine sulfate) extended-release tablets....
Teva Pharmaceutical has announced the FDA approved Vantrela ER (hydrocodone bitartrate) extended-release tablets [CII] formulated with Teva’s proprietary abuse deterrence...
Collegium Pharmaceutical announced the publication of results from the Phase III clinical trial of Xtampza ER (oxycodone extended-release capsules). The...
Neos Therapeutics, Inc. announced that the FDA has approved Adzenys ER (amphetamine) Extended-Release Oral Suspension. Neos Therapeutics is the only...
Egalet Corporation announced that the joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and...
The FDA has approved a new, harder-to-abuse formulation of Opana ER, the extended-release oxymorphone drug that is crush resistant from...
The FDA has accepted for review the new drug application (NDA) for the oral, extended-release hydrocodone therapy ZohydroER from Zogenix...
Osmotica Pharmaceutical announced that the FDA has approved Osmolex ER (amantadine HCl extended release), for the treatment of Parkinson's disease...